Skip to content

Study on Acupuncture Treatment of Perimenopausal Syndrome by Shu-Mu Point Pairing Method: A Randomized Controlled Trial

Study on Acupuncture Treatment of Perimenopausal Syndrome by Shu-Mu Point Pairing Method: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000689
Enrollment
Unknown
Registered
2025-04-10
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perimenopause

Interventions

Fenmotone group:Treated with oral fenmotone
Acupuncture group:Shu-mu acupuncture was used to treat the acupoints: Shenshu (BL23) Ganshu (BL18) Xinshu (BL15) Pishu (BL20) Jingmen (GB25) Juque (RN14) and Zhangmen (LR13) stage gate (LR14). All the

Sponsors

Shanghai TCM-Integrated Hospital Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Age in line with perimenopausal period (40-55 years old) women; 2. Meet the above diagnostic criteria of Chinese and Western medicine; 3. No organic disease uterus and bilateral ovaries intact; 4. Able to understand and cooperate with the completion of treatment evaluation and follow-up; 5. Agree and voluntarily participate in this study and sign informed consent in person.

Exclusion criteria

Exclusion criteria: 1. do not meet the above inclusion criteria; 2. known or suspected pregnancy; 3. unexplained vaginal bleeding: vaginal bleeding causes including neoplastic inflammatory iatrogenic traumatic and ovarian dysfunction; 4. known or suspected breast cancer. 5 Known or suspected sex hormone-dependent malignancy. 6 Active venous or arterial thromboembolic disease within the last 6 months. 7 Severe liver and kidney dysfunction. If repeated measurements of liver and kidney function are 2 to 3 times higher than normal values medical diagnosis and treatment are recommended first. (8) Patients with serious primary diseases such as cardiovascular lung liver kidney hematopoietic system and reproductive system; (9) Patients who have used hormone drugs psychotropic drugs and anticoagulant drugs in the past 1 month; (10) Patients who are conducting other drug clinical trials.

Design outcomes

Primary

MeasureTime frame
Self-rating Depression Scale;Menopause Rating Scale;

Secondary

MeasureTime frame
Menopause-specific Quality of Life;Self-rating Anxiety Scale;Serum Sex Hormones;Insomnia Severity Index;Traditional Chinese Medicine Syndrome Scoring Scale;

Countries

China

Contacts

Public ContactGuizhi Ma

Shanghai TCM-Integrated Hospital Shanghai University of TCM

Sandy@126.com18964746998

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026